CRBU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now: price remains in a broader downtrend (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia buy signals to front-run.", "Short-term momentum is trying to turn (MACD histogram positive and expanding), but it\u2019s not yet confirmed by trend structure; downside to S1 ~1.408 is still plausible.", "Options positioning is bullish (very low put/call ratios) and hedge funds increased buying sharply, but without a near-term catalyst/news flow this looks more like speculative sentiment than a clean entry.", "If you must act immediately (impatient entry), the risk/reward is not favorable versus nearby support; better setups would be either a reclaim of ~1.68 (R1) or a clean hold/reversal off ~1.41 (S1)."]
["Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5) \u2192 primary trend still down.", "Momentum: MACD histogram 0.00891 above zero and expanding \u2192 early bullish momentum attempt.", "RSI(6): ~49.98 neutral \u2192 no strong overbought/oversold edge.", "Levels: Pivot 1.546 (price ~1.535 slightly below), Resistance 1.683 (R1) then 1.768 (R2); Support 1.408 (S1) then 1.323 (S2).", "Pattern-based projection: modeled odds imply mild drift near-term (next day -0.29%, next week +0.37%) but weaker 1-month bias (-3.86%).", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: no signal on given stock today.\n- SwingMax: No signal on given stock recently."]
["Hedge funds: Buying increased +1731.04% QoQ \u2192 institutional accumulation signal.", "Analyst support: Recent initiations/coverage maintain Buy ratings and high long-term pipeline upside framing.", "Technical: MACD turning positive suggests a potential early reversal attempt."]
["No news in the recent week \u2192 no near-term event-driven catalyst to force a re-rate immediately.", "Primary trend remains bearish (moving average stack down); price is below pivot ~1.546.", "High implied volatility suggests the market expects large moves; without a catalyst this can work against immediate spot buyers.", "Statistical 1-month pattern bias points negative (-3.86%)."]
["Latest quarter: 2025/Q3.", "Revenue: $2.20M, up 8.60% YoY (modest growth).", "Net income: - $27.55M, down 20.57% YoY (loss widened).", "EPS: -0.30, down 21.05% YoY (deteriorating profitability).", "Overall: topline improving slightly, but losses expanding\u2014typical pre-commercial biotech profile, not a fundamental momentum story yet."]
["2026-02-02: Clear Street initiated Buy, PT $13 (pipeline/vispa-cel and CB-011 long-run upside).", "2026-01-06: BofA kept Buy but cut PT $8 \u2192 $6 (still constructive on biotech backdrop).", "Trend: Ratings stay positive (Buy/Buy), but one notable PT reduction recently \u2192 Wall St is bullish on long-term upside, less confident on near-term valuation/path."]
